Medscape
TOPLINE: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and fenofibrates are associated with a reduced risk for diabetic macular edema (DME) in patients with type 2 diabetes, while calcium channel blockers appear to increase the risk. METHODOLOGY: Researchers conducted a retrospective analysis of electronic medical records from the TriNetX health research network to evaluate how …
Read More
Diabetes Drugs and Eye Disease: These Protect, These Don’t
Georgianna Mayoral
09:19
TOPLINE: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and fenofibrates are associated with a reduced risk for diabetic macular edema (DME) in patients with type 2 diabetes, while calcium channel blockers appear to increase the risk. METHODOLOGY: Researchers conducted a retrospective analysis of electronic medical records from the TriNetX health research network to evaluate how
